Loading organizations...
§ Public · San Diego, CA, USA
Clinical-stage biotech company developing off-the-shelf allogeneic NK cell therapies for cancer and autoimmune diseases.
Artiva Biotherapeutics is a clinical-stage biotechnology company based in San Diego, California, that develops off-the-shelf allogeneic natural killer cell therapies for patients with cancer and autoimmune diseases. The publicly traded enterprise operates with a workforce of 104 employees and maintains a market capitalization of approximately $135 million following its recent transition to the public equities market. Prior to raising $167 million in its July 2024 initial public offering on the Nasdaq, the firm secured nearly $200 million in private venture funding. This private capital was provided by institutional lead investors including 5AM Ventures and venBio Partners. The organization utilizes a proprietary manufacturing platform to advance its lead clinical candidate, AlloNK, while maintaining strategic pharmaceutical development partnerships with corporate entities such as Merck and GC Cell. Artiva Biotherapeutics was founded in 2019 by Tom Farrell.
Artiva Biotherapeutics has raised $198.0M across 2 funding rounds.
Artiva Biotherapeutics has raised $198.0M in total across 2 funding rounds.
Artiva Biotherapeutics has raised $198.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $120M Series B | Venrock | 5AM Ventures, Frazier Healthcare Partners, VenBio Partners, Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Green Cross Holdings, Green Cross LabCell, Janus Henderson Investors, Logos Capital, RA Capital Management, RTW Investments, Surveyor Capital, Wellington Management | Announced |
| Jun 1, 2020 | $78M Series A | 5AM Ventures, Laura Stoppel | Frazier Healthcare Partners, VenBio Partners | Announced |
Artiva Biotherapeutics has raised $198.0M in total across 2 funding rounds.
Artiva Biotherapeutics's investors include Venrock, 5AM Ventures, Frazier Healthcare Partners, venBio, Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Green Cross Holdings, Green Cross LabCell, Janus Henderson Investors, Logos Capital.
Artiva Biotherapeutics (NASDAQ: ARTV) is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers.[1][2][3][4] Its lead product, AlloNK®, is a non-genetically modified, cryopreserved, allogeneic NK cell therapy designed for combination with B-cell targeted monoclonal antibodies (mAbs) to enhance antibody-dependent cellular cytotoxicity, targeting B-cell driven conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), lupus nephritis (LN), and Sjögren’s disease.[1][2][3][4] AlloNK is administered in outpatient settings without hospitalization, addressing access barriers of autologous therapies through scalable, off-the-shelf manufacturing that produces thousands of doses from a single umbilical cord blood unit, with capacity for over 1,000 autoimmunity patients annually at its San Diego facility.[1][2] The company serves patients with devastating autoimmune diseases and cancers, solving problems of limited efficacy, severe toxicities, and inaccessibility in current cell therapies by prioritizing safety, effectiveness, and broad community availability.[1][3]
Artiva's pipeline includes ongoing clinical trials—two company-sponsored basket trials and one investigator-initiated trial for autoimmune diseases—plus CAR-NK candidates for solid and hematologic cancers, showing growth momentum via its manufacturing-first approach partnered with GC Cell Corporation.[1][2][3]
Artiva Biotherapeutics emerged from a manufacturing-first vision to overcome limitations in cell therapy accessibility, leveraging over a decade of process development by strategic partner GC Cell Corporation.[1] The company is headquartered in San Diego, California, where it built its own facility to scale production of allogeneic NK cells from umbilical cord blood, enabling off-the-shelf therapies unlike patient-specific autologous approaches.[1][2] Key pivotal moments include advancing AlloNK into three ongoing clinical trials for B-cell driven autoimmune diseases and expanding the pipeline to CAR-NK for cancers, driven by peer-reviewed evidence on NK cells' B-cell depletion potential for drug-free remission.[1][3] While specific founders are not detailed in available sources, Artiva's evolution reflects a commitment to transforming cell therapy from "for the few" to broadly accessible, building on a decade of NK cell manufacturing innovation.[1][3]
Artiva rides the cell therapy revolution in autoimmune diseases and oncology, where recent advances show dramatic responses in hematological malignancies but face hurdles like toxicities and manufacturing scalability.[3] Timing aligns with growing evidence for B-cell depletion via NK cells plus mAbs, enabling drug-free remission in autoimmune conditions amid rising demand for accessible alternatives to complex autologous CAR-T therapies.[1] Market forces favoring Artiva include biotech shifts toward allogeneic platforms for cost-efficiency and the expanding autoimmune market (e.g., RA, SLE), plus NK cells' safety profile over gene-edited options.[1][2][3] It influences the ecosystem by pioneering NK scalability, potentially democratizing cell therapy beyond elite centers and inspiring manufacturing innovations for broader adoption.[1][3]
Artiva is positioned for clinical readouts from its AlloNK trials and CAR-NK advancement, with Q3 2025 financials highlighting business momentum toward commercialization.[5] Trends like allogeneic NK expansion and autoimmune cell therapy uptake will shape its path, potentially evolving its influence from clinical pioneer to market leader in accessible NK therapies. As cell therapy moves from "for the few" to widespread use, Artiva's manufacturing edge could redefine treatment for millions with autoimmune diseases and cancers, fulfilling its mission for effective, safe access.[1][3]